Cardiff Oncology, Inc. (CRDF)
| Market Cap | 56.49M -62.6% |
| Revenue (ttm) | 559,000 +11.6% |
| Net Income | -37.68M |
| EPS | -0.54 |
| Shares Out | 77.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 205,373 |
| Open | 0.7276 |
| Previous Close | 0.7276 |
| Day's Range | 0.7107 - 0.7350 |
| 52-Week Range | 0.7107 - 3.3100 |
| Beta | 1.56 |
| Analysts | Buy |
| Price Target | 6.28 (+765.31%) |
| Earnings Date | Nov 12, 2026 |
About CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CR... [Read more]
Financial Performance
In 2025, Cardiff Oncology's revenue was $593,000, a decrease of -13.18% compared to the previous year's $683,000. Losses were -$45.88 million, 0.93% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CRDF stock is "Buy." The 12-month stock price target is $6.28, which is an increase of 765.31% from the latest price.
News
Cardiff Oncology reports Q3 EPS (12c), consensus (13c)
Reports Q3 revenue $171,000, consensus $86,430. “We’re greatly encouraged by the performance of onvansertib in first-line RAS-mutated mCRC. As the data mature, the benefit of onvansertib in combinatio...
Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update
Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms
Cardiff Oncology Quarterly report: Q3 2026
Cardiff Oncology has published its Q3 2026 quarterly earnings report on November 12, 2026.
Cardiff Oncology Earnings release: Q3 2026
Cardiff Oncology released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Cardiff Oncology small cell lung cancer treatment gets orphan status
Cardiff Oncology (CRDF) received FDA orphan designation for onvansertib as a treatment of small cell lung cancer, according to a post to the agency’s website.
Cardiff Oncology to Participate in the UBS Global Biopharma Conference
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance...
Cardiff Oncology names Leila Alland interim chief medical officer
Cardiff Oncology (CRDF) announced the appointment of Leila Alland as interim chief medical officer. Alland is a seasoned biopharmaceutical executive who has led multiple oncology drug development prog...
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced t...
Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia
SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced...
Cardiff Oncology treatment of chronic myelomonocytic leukemia gets orphan status
Cardiff Oncology’s (CRDF) onvansertib was granted FDA orphan designation as a treatment of chronic myelomonocytic leukemia, according to a post to the agency’s website.
Cardiff Oncology upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Cardiff Oncology (CRDF) to Buy from Neutral with a $9 price target The company reached a settlement with Nerviano and amended its 2017 license agreement, resolving all…
Cardiff Oncology Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The settlement preserves exclusive worldwide rights and decision-making while extending the royalty period. A ~640-patient Phase III trial of onvansertib plus FOLFIRI/bevacizumab is targeted to start in 1Q 2027, pending funding; ORR data may support accelerated approval.
Cardiff Oncology, Nerviano Medical Sciences reach settlement
Cardiff Oncology (CRDF) and Nerviano Medical Sciences announced that they have reached a settlement and amended their 2017 exclusive license agreement, resolving all outstanding disputes between the t...
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l.
Cardiff Oncology to Participate in September 2026 Conferences
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of canc...
Cardiff Oncology Proxy statement: Proxy filing
Cardiff Oncology filed a proxy statement on August 26, 2026, providing details for shareholder voting and corporate governance matters.
Cardiff Oncology Proxy statement: Proxy filing
Cardiff Oncology filed a proxy statement on August 26, 2026, providing details for shareholder voting and corporate governance matters.
Cardiff Oncology reports Q2 EPS (14c), consensus (16c)
Reports Q2 revenue $104,000, consensus $62,780. “The second quarter was an important period of progress for Cardiff, highlighted by the presentation of positive Phase 2 data at ASCO and our…
Cardiff Oncology downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Cardiff Oncology (CRDF) to Market Perform from Outperform. Post-Q2 results, the firm said the company’s fundamentals have deteriorated materially. The firm added that it belie...
Cardiff Oncology Proxy statement: Proxy filing
Cardiff Oncology filed a proxy statement on August 14, 2026, providing details for shareholder voting and corporate governance matters.
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCR...
Cardiff Oncology Quarterly report: Q2 2026
Cardiff Oncology has published its Q2 2026 quarterly earnings report on August 11, 2026.
Cardiff Oncology Earnings release: Q2 2026
Cardiff Oncology released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Cardiff Oncology announces $10M registered direct offering
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Cardiff Oncology Announces $10 Million Registered Direct Offering
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies,...